Metropolis Healthcare Ltd Q2FY26 – The ₹429-Crore Lab Report That Even Your Blood Sample Can’t Escape From
1. At a Glance
Metropolis Healthcare Ltd — the diagnostics veteran that pokes your veins and your wallet with equal precision — just dropped its Q2FY26 report, and let’s just say it came with a clean bill of financial health. The company clocked revenue of ₹429 crore (up 23% YoY), EBITDA of ₹109 crore (up 19% YoY), and PAT of ₹53 crore (up 13% YoY). A decent performance for a sector that often catches colds when the economy sneezes.
At a current market price of ₹2,031 and a market cap of ₹10,524 crore, the stock is trading at a nosebleed-inducing P/E of 78.9x, which means investors are treating this lab stock more like an AI unicorn than a diagnostic company. ROE sits at 10.5%, ROCE at 13.4%, and the company just declared an interim dividend of ₹4 per share (because what’s better than sharing profits made from testing everyone else’s?).
Metropolis is still the second-largest diagnostics brand in India, right behind Dr. Lal PathLabs, but with an asset-light network of 167 labs and 3,854 service centers across 488 towns — this lab is spreading faster than a seasonal flu.
So what’s brewing in those test tubes? Let’s dissect.
2. Introduction – The Anatomy of a Diagnostic Darling
Metropolis Healthcare is the kind of company that thrives when people sneeze, cough, and Google “weird chest pain.” It’s part of an industry where every bad diet decision, every sleepless night, and every cholesterol-laden samosa indirectly contributes to the topline.
This quarter, the company seems to have found the right mix of operational hygiene and margin recovery. While sales surged 23% YoY to ₹429 crore, PAT rose to ₹53 crore, riding on efficiency, wellness packages, and a slightly more health-conscious post-COVID customer base.
But beneath the clean medical reports lies a complex business model — one that’s equal parts science, logistics, and brand trust. After acquiring Hitech Diagnostics (₹636 crore in FY22), Metropolis went on a shopping spree, adding Scientific Pathology, Dr. Ahujas’ Pathology & Imaging Centre, and Ambika Pathology in FY25–26. When your growth strategy reads like a pathology chain acquisition bingo card, you know the lab coat’s pockets are deep.
Despite the acquisitions, management continues to swear by its asset-light model — 92% of the central network and 18% of lab network now run on-lease, which basically means “Why buy a lab when you can rent it and still charge premium rates for your glucose test?”
So, yes, the needle is sharp, and the margins are steady — but does it justify a 78x P/E? Hold that blood sample; we’ll test that hypothesis soon.
3. Business Model – WTF Do They Even Do?
Think of Metropolis as the “Uber of Diagnostics,” but with pipettes instead of steering wheels. Their empire rests on three pillars: Pathology tests, Wellness packages, and B2B hospital tie-ups.
Here’s the split:
Core Business (including Hi-Tech tests) contributes ~98% of revenue.
PPP contracts and Covid-related tests now form less than 2% combined. (Yes, COVID was the best intern they ever had, but he’s gone now.)
Revenue segmentation tells us the story — the B2B segment still accounts for ~51% of revenue, meaning Metropolis spends a lot of time chasing hospital and clinic payments rather than retail patients. That’s why receivables can sometimes look like a marathon runner — long and stretched.
However, Premium Wellness packages (growing at 27%) and Specialized Tests (up 12%) are the new blood donors of growth. The company is essentially trying to convince healthy people to test more often — because “prevention” pays more consistently than “treatment.”
Internationally, they’ve built a respectable network across Kenya, Ghana, Zambia, Tanzania, and Uganda, which means your blood report might have a passport stamp soon.
4. Financials Overview
Source table
Metric
Q2FY26
Q2FY25
Q1FY26
YoY %
QoQ %
Revenue
₹429 Cr
₹349 Cr
₹400 Cr
22.9%
7.3%
EBITDA
₹109 Cr
₹92 Cr
₹100 Cr
18.5%
9.0%
PAT
₹53 Cr
₹47 Cr
₹49 Cr
12.8%
8.2%
EPS (₹)
10.2
9.0
9.3
13.3%
9.7%
Annualised EPS = ₹40.8 → At CMP ₹2,031, P/E ≈ 49.8x on forward basis.
Commentary: Margins are slowly recovering from post-COVID fatigue. The 26% OPM looks healthy (pun intended). PAT margins hover near 12%, reflecting disciplined operations despite acquisitions. Still, one wonders if Metropolis has become the Apple of diagnostics — all brand, low innovation, high
